Another pharma boost for genomics

The latest demonstration of the pharmaceutical industry's interest in genomics is Pfizer Inc.'s $9 million equity investment in Incyte Pharmaceuticals Inc. (IPI) for non-exclusive access to IPI's gene database and high-throughput gene sequencing and analysis technology.

Pfizer will pay $15.8 million in research funding and database access charges